A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2 Hour Intravenous Infusion on Two Dose Schedules in Patients With Advanced Solid Malignancies.

Trial Profile

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2 Hour Intravenous Infusion on Two Dose Schedules in Patients With Advanced Solid Malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2009

At a glance

  • Drugs Barasertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Jun 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Jun 2009 Planned end date changed from 1 May 2008 to 1 Apr 2009 as reported by ClinicalTrials.gov.
    • 16 Apr 2008 Status changed from recruiting to in progress according to clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top